-transparent.png){kind=logo}
Sixty postmenopausal women with advanced breast cancer entered a phase II study, evaluating idarubicin (IDA) in a weekly schedule. Starting dose was 22.5 mg/m2, and median age was 65 years. Five patients were considered ineligible and the response rate among 55 eligible patients was 33%. Median time to treatment failure was 19 weeks and median duration of tumor regression for 18 responding patients was 40 weeks. Hematologic toxicity was moderate and non-hematologic toxicity was mild. The study shows that IDA, administered orally in a weekly schedule, has pharmacodynamic properties comparable to IDA in a 3-weekly schedule and to doxorubicin in the treatment of advanced breast cancer.
L Bastholt, and
M Dalmark, and
A Jakobsen, and
C C Gadeberg, and
E Sandberg, and
H T Mouridsen
January 1992,
Acta oncologica (Stockholm, Sweden),
L Bastholt, and
M Dalmark, and
A Jakobsen, and
C C Gadeberg, and
E Sandberg, and
H T Mouridsen
January 1986,
Investigational new drugs,
L Bastholt, and
M Dalmark, and
A Jakobsen, and
C C Gadeberg, and
E Sandberg, and
H T Mouridsen
December 1986,
Cancer treatment reports,
L Bastholt, and
M Dalmark, and
A Jakobsen, and
C C Gadeberg, and
E Sandberg, and
H T Mouridsen
October 1990,
American journal of clinical oncology,
L Bastholt, and
M Dalmark, and
A Jakobsen, and
C C Gadeberg, and
E Sandberg, and
H T Mouridsen
January 1988,
Cancer chemotherapy and pharmacology,
L Bastholt, and
M Dalmark, and
A Jakobsen, and
C C Gadeberg, and
E Sandberg, and
H T Mouridsen
February 1997,
European journal of cancer (Oxford, England : 1990),
L Bastholt, and
M Dalmark, and
A Jakobsen, and
C C Gadeberg, and
E Sandberg, and
H T Mouridsen
April 1987,
European journal of cancer & clinical oncology,
L Bastholt, and
M Dalmark, and
A Jakobsen, and
C C Gadeberg, and
E Sandberg, and
H T Mouridsen
January 1989,
European journal of cancer & clinical oncology,
L Bastholt, and
M Dalmark, and
A Jakobsen, and
C C Gadeberg, and
E Sandberg, and
H T Mouridsen
August 1986,
Onkologie,
L Bastholt, and
M Dalmark, and
A Jakobsen, and
C C Gadeberg, and
E Sandberg, and
H T Mouridsen
April 1984,
Cancer treatment reports,
